KPRX (Kiora Pharmaceuticals) OCF Yield %: -92.54 (As of Jun. 27, 2026)


KPRX Kiora Pharmaceuticals Inc KPRX
34 GF Score
Price $2.54
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals OCF Yield %?

Kiora Pharmaceuticals KPRX -0.78% 34 OCF Yield % is -92.54 as of Jun. 27, 2026. GuruFocus rates KPRX with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,419 Biotechnology companies, Kiora Pharmaceuticals ranks worse than 89.71% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Kiora Pharmaceuticals's Trailing 12-Month Cash Flow from Operations is $-10.42 Mil, and Market Cap is $11.26 Mil. Therefore, Kiora Pharmaceuticals's OCF Yield % for today is -92.54%.

The historical rank and industry rank for Kiora Pharmaceuticals's OCF Yield % or its related term are showing as below:

KPRX' s OCF Yield % Range Over the Past 10 Years
Min: -7190.88   Med: -47.39   Max: 108.42
Current: -92.54


During the past 13 years, the highest OCF Yield % of Kiora Pharmaceuticals was 108.42%. The lowest was -7190.88%. And the median was -47.39%.

KPRX's OCF Yield % is ranked worse than
89.71% of 1419 companies
in the Biotechnology industry
Industry Median: -8.48 vs KPRX: -92.54

Kiora Pharmaceuticals's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Kiora Pharmaceuticals OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Kiora Pharmaceuticals OCF Yield % Related Terms


Kiora Pharmaceuticals OCF Yield % Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals OCF Yield % Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.11 -168.90 -237.47 86.43 -134.41

Kiora Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -119.74 -153.86 -53.35 -117.66 -164.07

KPRX vs BRTX, INTS, ERNA: OCF Yield % Comparison

For the Biotechnology subindustry, Kiora Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's OCF Yield % falls into.


KPRX
34GF Score
Kiora Pharmaceuticals Inc KPRX
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Kiora Pharmaceuticals's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-9.961 / 7.41114
=-134.41%

Kiora Pharmaceuticals's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-3.161 * 4 / 7.70649
=-164.07%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -92.54 mean?
Kiora Pharmaceuticals (KPRX) has a OCF Yield % of -92.54 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Kiora Pharmaceuticals and its competitors. According to the industry distribution chart, Kiora Pharmaceuticals ranks #1273 out of 1419 companies in the Biotechnology industry, placing it in the top 89.7%.
Is Kiora Pharmaceuticals' OCF Yield % too high?
Kiora Pharmaceuticals' current OCF Yield % is -92.54. Based on the distribution chart, Kiora Pharmaceuticals ranks #1273 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' OCF Yield % compare to BRTX and INTS?
According to the Biotechnology industry distribution chart, Kiora Pharmaceuticals ranks #1273 out of 1419 companies for OCF Yield %. This places Kiora Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current OCF Yield % is -92.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current OCF Yield % of -92.54. The current OCF Yield % is -92.54. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current OCF Yield % is -92.54 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for KPRX

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.54
Price